MYC and adrenal cortex carcinoma: Another prior study suggests the existence of two molecular subgroups of ACC (ACC‐I and ACC‐II) with dramatically differing prognoses that are driven by mutated signaling pathways involving MYC hyperactivation versus p63 suppression [23].